Enoxaparin (Lovenox, Clexane)
Other Medications · Approved since 1993
Description
Enoxaparin is a low molecular weight heparin anticoagulant used for venous thromboembolism prophylaxis and treatment in colorectal cancer patients. In CRC care, it serves as supportive therapy to prevent blood clots that commonly occur due to cancer-induced hypercoagulability and prolonged immobilization during treatment. The clinical trials indicate its use for thromboprophylaxis in cancer patients with elevated tissue factor-bearing microparticles and for preventing radiation-induced liver toxicity when combined with other hepatoprotective agents.
Mechanism of Action
Enoxaparin binds to antithrombin III and accelerates its inhibition of factor Xa and thrombin (factor IIa), with preferential activity against factor Xa. This anticoagulant effect disrupts the coagulation cascade, preventing fibrin formation and subsequent clot development in cancer patients who have increased thrombotic risk.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Lovenox, Clexane |
| Category | Other Medications |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS other indication |
| Administration | Subcutaneous |
| Year Approved | 1993 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.